Abstract
Information on treatment of COVID-19 infection in renal transplant recipients is scarce, especially in symptomatic patients and patients with recent major clinical events. This group of patients suffers from different opportunistic infections which may coexist with COVID-19. Currently available expert opinions suggest reduction of immunosuppression therapy for renal transplant recipients with symptomatic COVID-19 infection with either antiviral drugs, hydroxychloroquine and/or azithromycin. Inspired by our experience in treatment of CMV pneumonia and literature data on the potential benefit of convalescent plasma for treatment of different viral diseases we suggest use of the hyperimmune anti-CMV gamma globulins in addition to other available therapies. Besides the immunosuppression reduction which is supposed to be beneficial, immunoglobulins with their immunomodulatory effects and possible antiviral role, may increase a possibility for favorable outcome.
Keywords: COVID-19; Hyperimmune anti-CMV globulin; Renal transplantation; SARS-CoV-2.
【저자키워드】 COVID-19, SARS-CoV-2, Renal transplantation, Hyperimmune anti-CMV globulin, 【초록키워드】 Treatment, convalescent plasma, SARS-CoV-2, therapy, Hydroxychloroquine, Pneumonia, antiviral drugs, Immunosuppression, outcome, Immunoglobulin, COVID-19 infection, symptomatic, Patient, CMV, viral disease, Therapies, opportunistic infection, reduction, renal, recipient, immunomodulatory effect, antiviral role, benefit, hyperimmune, addition, events, symptomatic patient, with COVID-19, 【제목키워드】 Treatment, convalescent plasma, hyperimmune, Can,